EU Market Access 2021: What’s in Store for Orphan Drugs and ATMPs? Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will help address key market access trends likely to occur in 2021 in the context of commercializing orphan drugs and ATMPs in Europe, as well as implications of the new EU Pharmaceutical Strategy for the industry. Attendees will learn about key considerations for manufacturers to optimize their market access strategy and implementation plans.

The global population is now on the edge of a major shift in healthcare access, delivery and engagement. It is time to adapt or crash.

2021 has the potential to be a record year for orphan drugs and advanced therapy medicinal products (ATMPs) in Europe. With the hope of a world in which COVID-19 is a manageable disease comes the promise of ground-breaking new therapies and innovative approaches to digital healthcare. However, these will enter into an access environment under turmoil and change: a new EU Pharmaceutical Strategy, potential changes to orphan drug legislation and continual evolution of health technology assessment (HTA) processes and digital healthcare. The global population is now on the edge of a major shift in healthcare access, delivery and engagement. It is time to adapt or crash.

In this webinar, the featured speakers will bring a fresh, forward-looking perspective to the changing regulatory environment in Europe for orphan drugs and ATMPs and the key access trends expected in 2021. Through a mix of case examples and direct experiences, they will highlight insights into likely changes as a result of a greater number of ATMPs seeking commercialization, the EU Pharmaceutical Strategy and associated changes to the orphan drug legislation. Importantly, the webinar panelists will recommend key considerations for manufacturers to optimize preparation of future orphan drug and ATMP launches.

Join Alexander Natz, EUCOPE Secretary General; and Sophie Schmitz, Managing Partner, Partners4Access, in a live webinar on Wednesday, January 13 at 11am EST (4pm GMT/UK) to gain valuable insights into changes to the regulatory landscape expected in the coming year and advice on how sponsors can optimize their commercialization strategy for orphan drugs and ATMPs in Europe.

For more information, or to register for this event, visit EU Market Access 2021: What’s in Store for Orphan Drugs and ATMPs?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website